The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system

Pharmacology and Therapeutics

Volumn 93, Issue 1, 2002, Pages 51-75

  Pugsley, Michael K ^a  

^a XOMA Corporation   (United States)

Author keywords

Arylacetamide; Cardiac arrhythmias; Hypertension; Ischaemic preconditioning; Opioid; Review

Indexed keywords

1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 5 HYDROXYDECANOIC ACID; 5,9 DIETHYL 2 (3 FURYLMETHYL) 2' HYDROXY 6,7 BENZOMORPHAN; 7 BENZYLIDENENALTREXONE; DELTA OPIATE RECEPTOR; DEXTRORPHAN; ENADOLINE; GLIBENCLAMIDE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINE; MR 266; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; N (3 FURYLMETHYL)NORMETAZOCINE; N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZO[B]THIOPHENE 4 ACETAMIDE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALOXONE; NORBINALTORPHIMINE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE PEPTIDE; OPIATE RECEPTOR; PD 129289; QUADAZOCINE; SPIRADOLINE MESILATE; UNCLASSIFIED DRUG;

ANALGESIA; ARRHYTHMOGENESIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DRUG ANALYSIS; DRUG MECHANISM; HEART; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HUMAN; HYPERTENSION; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ARRHYTHMIA; CARDIOVASCULAR PHYSIOLOGY; CENTRAL NERVOUS SYSTEM; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; ISCHEMIC PRECONDITIONING; MOLECULAR STRUCTURE; MYOCARDIAL ISCHEMIA; NARCOTIC ANTAGONISTS; NARCOTICS; PEPTIDES; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036126813     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00165-1     Document Type: Review

References (215)

1. Intracerebroventricular treatment with an antisense oligodeoxynucleotide to kappa-opioid receptors inhibited kappa-agonist-induced analgesia in rats
2. Antagonism of stimulation-produced analgesia by naloxone, a narcotic antagonist
3. Cardiac electrophysiological effects of U-50,488H on guinea-pig papillary muscle
4. Indentification of benzomorphan-κ opiate receptors in cerebral arteries which subserve relaxation
5. Nonopioid actions of the κ-opioid receptor agonists, U-50,488H and U-69,593, on electrophysiologic properties of hippocampal CA3 neurons in vitro
6. Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate
7. Opioid peptides and the heart
8. Screening for opioids in dog heart
9. Pericardial repair depresses canine cardiac catecholamines and met-enkephalin
10. Synthetic analgesics: Stereochemical considerations
11. Antiarrhythmic evaluation of naloxone against acute coronary occlusion-induced arrhythmias in pigs
12. 2-adrenoceptor blockade
13. The antiarrhythmic and cardiac electrophysiological effects of buprenorphine
14. Molecular and cellular mechanisms of myocardial stunning
15. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide
16. The nitric oxide hypothesis of late preconditioning
17. Influence of the optical isomers (+)- and (-)-naloxone on beating frequency, contractile force and action potentials of guinea-pig isolated cardiac preparations
18. Enkephalin inhibits vagal control of heart rate, contractile force and coronary blood flow in the canine heart in vivo
19. Inhibition of ionic currents in frog node of ranvier treated with naloxone
20. Benzomorphan sites are ligand recognition sites of putative epsilon-receptors
21. Molecular cloning and functional expression of a μ-opioid receptor from rat brain
22. + channel
23. Blockade of U50,488H analgesia by antisense oligodeoxynucleotides to a kappa-opioid receptor
24. Naloxone blockade of myocardial ischemic preconditioning is stereoselective
25. Naloxone blockade of myocardial ischemic preconditioning does not require central nervous system participation
26. Extension of tissue survival time in multiorgan block preparation with a delta opioid DADLE ([D-Ala2, D-Leu5]-enkephalin)
27. Opioid receptor coupled second messenger systems
28. + channels protect the myocardium against ischemia/reperfusion damage
29. Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease
30. Angina: Who needs it? Cardioprotection in the preconditioning era
31. Atrial natriuretic factor: A hormone produced by the heart
32. Preconditioning induction trigger evokes cardioprotection via the opiate receptor
33. Model systems for the study of seven-transmembrane-segment receptors
34. The effects of the κ-opioid agonist U50,488H on guinea pig ventricular myocytes
35. Characterization of the high affinity [3H]nociceptin binding site in membrane preparations of rat heart: Correlations with the non-opioid dynorphin binding site
36. Distinct components of morphine effects on cardiac myocytes are mediated by the kappa and delta opioid receptors
37. Vascular effects of some opioid receptor agonists
38. Cloning of a delta opioid receptor by functional expression
39. Naloxone inhibits early arrhythmias resulting from acute coronary ligation
40. Antiarrhythmic actions of meptazinol, a partial agonist at opiate receptors, in acute myocardial ischaemia
41. Central effects of mu, delta, and kappa receptor agonists in haemorrhagic shock
42. Relationship between plasma atrial natriuretic factor and opioid peptide levels in healthy subjects and in patients with acute congestive heart failure
43. μ-, δ-, and κ-opioid receptors and their subtypes. A critical review with emphasis on radioligand binding experiments
44. Naloxone has local anesthetic effects on canine cardiac Purkinje fibres
45. Nature of the morphine receptor present in the squid axon
46. ATP channels
47. + channels. Possible mechanism of cardioprotection
48. Oligomerization of mu and delta opioid receptors
49. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain
50. Selective pulmonary and venous smooth muscle relaxation by furosemide: A comparison with morphine
51. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs
52. + channels and myocardial preconditioning
53. κ-Opioid receptors also increase potassium conductance
54. Demonstration of an early and a late phase of ischemic preconditioning in mice
55. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene
56. Cardiovascular depressant effects of the kappa opioid receptor agonists U-50,488H and spiradoline mesylate
57. Inhibitory effect of spiradoline, a kappa opioid receptor agonist, on calcium-induced contraction and the intracellular calcium concentration in procine coronary artery
58. Arrhythmogenic, antiarrhythmic and inotropic properties of opioids. Effects of piritramide, pethidine and morphine compared on heart muscle isolated from rats
59. κ-opioid receptors couple to inwardly rectifying potassium channels when coexpressed by Xenopus oocytes
60. Ischaemia, extracellular potassium accumulation and the cardiac electrophysiological effects of dl and d-naloxone
61. Short-term effects of naloxone on hemodynamics and baroreflex function in conscious dogs with pacing-induced congestive heart failure
62. Cardiovascular effects of endogenous opiate systems
63. Naloxone reversal of endotoxin hypotension suggests a role of endorphins in shock
64. Phencyclidine-like discriminative effects of opioids in the rat
65. Naloxone inhibits arrhythmias induced by coronary artery occlusion and reperfusion in anaesthetized dogs
66. Identification of two related pentapeptides from the brain with potent opiate agonist activity
67. The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues
68. κ-Opiates and urination: Pharmacological evidence for an endogenous role of the κ-opiate receptor in fluid and electrolyte balance
69. Opioid receptor independent effects of morphine on membrane currents in single cardiac myocytes
70. Assessment in the guinea pig ileum and mouse vas deferens of benzomorphans which have strong antinociceptive activity but which do not substitute for morphine in the dependent monkey
71. Beta-endorphin sensitive opioid receptors in the rat tail artery
72. Comparison of cardiovascular effects of mu- and delta-opioid receptor antagonists in dogs with congestive heart failure
73. Direct effects of fentanyl on canine coronary artery rings
74. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat
75. Effects of kappa opiate agonist on neurochemical and neuroendocrine indices: Evidence for kappa receptor subtypes
76. G-protein-coupled receptor heterodimerization modulates receptor function
77. Negative chronotropic but no antiarrhythmic effect of (+)- and (-)-naloxone in rats and guinea pigs
78. Effect of U-50,488H on the contractile response of cardiomypathic hamster ventricular myocytes
79. Nitric oxide and cardiac function
80. Opioids: First lessons from knockout mice
81. The δ-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization
82. Identification of a human delta opioid receptor: Cloning and expression
83. Molecular biology and pharmacology of cloned opioid receptors
84. Endogenous opioid mechanisms in hypothalamic blood flow autoregulation during haemorrhagic hypotension and angiotensin-induced acute hypertension in cats
85. Agonists and antagonists bind to different domains of the cloned kappa opioid receptor
86. Dynorphin-selective inhibition of adenylyl cyclase in guinea pig cerebellum membranes
87. Opiate binding in rat hearts: Modulation of binding after hemorrhagic shock
88. Analgesic activity of spiradoline mesylate (U-62,066E), a kappa opioid agonist in mice
89. Effects of spiradoline mesylate, a selective κ-opioid-receptor agonist, on the central dopamine system with relation to mouse locomotor activity and analgesia
90. Properties of a selective kappa agonist, U-50,488H
91. z coupling to the rat κ-opioid receptor
92. Negative feedback of opioid peptide receptor stimulation on β-adrenergic effects in heart cells
93. Evidence for the presence of enkephalins in the heart
94. Diuresis and suppression of vasopressin by kappa opioids: Comparison with mu and delta opioids and clonidine
95. Endogenous opioid peptides and cardiac arrhythmias
96. Stereospecific antiarrhythmic effects of naloxone against myocardial ischaemia and reperfusion in the dog
97. Consequences of opiate agonist and antagonist in myocardial ischaemia suggest a role of endogenous opioid peptides in ischaemic heart disease
98. Pharmacological profile of PD 117,302, a selective κ-opioid agonist
99. ATP channels
100. The role of endogenous opioids in congestive heart failure: Effects of nalmefene on systemic and regional hemodynamics in dogs
101. Cardiac KATP channels and ischemic preconditioning: Current perspectives
102. Effects of mu-, delta- and kappa-opioid antagonists in atrial preparations from nonfailing and failing human hearts
103. Endogenous opioid peptides: Multiple agonists and receptors
104. Role of endogenous opioids in heart failure
105. NO news is good news
106. The effects of drugs interacting with opioid receptors on ischaemic arrhythmias in anaesthetised rats
107. Isolation of a human κ opioid receptor cDNA from placenta
108. Anatomy of CNS opioid receptors
109. On the presence of opioid receptors in guinea-pig ventricular tissue
110. Interaction of co-expressed mu- and delta-opioid receptors in transfected rat pituitary GH(3) cells
111. Opioid antagonists
112. Pharmacology of opioids
113. The effects of morphine and nalorphine-like drugs on the non-dependent and morphine-dependent chronic spinal dog
114. In pursuit of antisense
115. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene
116. 2]deltorphin II in mice: Evidence for delta receptor subtypes
117. Role of endogenous opioid peptides in the acute adaptation to hypoxia
118. Delta-1 opioid receptor dependence of acute hypoxic adaptation
119. Delta-1 opioid agonist acutely increases hypoxic tolerance
120. Effects of rat brain kappa 1- and kappa 2-opioid receptors after chronic treatment with non-peptide kappa-agonists
121. Cloning and pharmacological characterization of a rat kappa opioid receptor
122. A chimeric study of the molecular basis of affinity and selectivity of the κ and the δ opioid receptors: Potential role of extracellular domains
123. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor
124. Localization of pro-opiomelanocortin mRNA transcripts and peptide immunoreactivity in rat heart
125. Cloning and expression of a cDNA for the rat κ-opioid receptor
126. Voltage-dependent effects of opioid peptides on hippocampal CA3 pyramidal neurons in vitro
127. Opioid antagonist modulation of ischaemia-induced ventricular arrhythmias: A peripheral mechanism
128. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium
129. cDNA cloning and pharmacological characterization of an opioid receptor with high affinities for κ-subtype-selective ligands
130. Affinity of drugs and peptides for U-69,593-sensitive and U-69,593-insensitive kappa opioid binding sites: The U-69,593-insensitive site appears to be the beta-endorphin-specific epsilon receptor
131. Opioid receptor types and membrane ion channels
132. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels
133. Primary structure and tissue distribution of the orphanin FQ precursor
134. Effect of the opioid kappa-receptor agonist U50,488H on the secretion of arginine vasopressin
135. Activation and inhibition of the endogenous opioid system in human heart failure
136. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1
137. Stereospecific antiarrhythmic effect of opioid receptor antagonists in myocardial ischaemia
138. Pharmacological mechanisms of opioid analgesics
139. Multiple mu opioid receptors
140. A new ECG measure (RSh) for detecting possible sodium channel blockade in vivo in rats
141. Kappa opioid receptors stimulate phosphoinositide turnover in rat brain
142. Opiate receptor: Demonstration in nervous tissue
143. Diuretic actions in man of a selective kappa opioid agonist: U-62,066E
144. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints
145. Regulatory peptides as modulators of vagal influence on cardiac rhythm
146. A new concept on the mode of interaction of narcotic analgesics with receptors
147. Cellular and subcellular actions of opioids in the heart
148. Naloxone blockade of sodium currents expressed in Xenopus oocytes
149. + channel blocking actions of the novel class I anti-arrhythmic agent RSD 921
150. Cardiovascular actions of the kappa receptor agonist, U-50,488H, in the absence and presence of opioid receptor blockade
151. Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion
152. Cardiovascular actions of U-50,488H and related kappa agonists
153. Electrophysiological and antiarrhythmic actions of the kappa agonist PD129290, and its R,R (+) enantiomer
154. An electrophysiological basis for the antiarrhythmic actions of the κ-opioid receptor agonist U-50,488H
155. Do related kappa agonists produce similar effects on cardiac ion channels?
156. The sodium channel blocking properties of spiradoline, a κ-receptor agonist, are responsible for its antiarrhythmic action in the rat
157. Potent and use-dependent block of cardiac sodium channels by U-50,488H, a benzeneacetamide kappa opioid receptor agonist
158. Effect of antiarrhythmic and analgesic drugs on the effective refractory period of guinea-pig isolated atria and ventricular strips
159. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors
160. Orphanin FQ: A neuropeptide that activates an opioid-like G protein-coupled receptor
161. Molecular biology of opioid receptors
162. Mechanism of diruetic action of spiradoline (U-62,066E) - A kappa opioid receptor agonist in the human
163. Ischemic preconditioning of the vasculature: An overlooked phenomenon for protecting the heart?
164. Nonopiate effect of naloxone on cardiac muscle contractility
165. Opiate receptor antagonism in right-sided congestive heart failure. Naloxone exerts salutary hemodynamic effects through its action on the central nervous system
166. Anti-arrhythmic activities of opioid agonists and antagonists and their stereoisomers
167. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts
168. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart
169. Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart
170. Ischemic preconditioning and morphine-induced cardioprotection involve the delta (δ)-opioid receptor in the intact rat heart
171. Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors
172. ATP channels
173. Comparison of cardiovascular responses to intra-hippocampal mu, delta and kappa opioid agonists in spontaneously hypertensive rats and isolation-induced hypertensive rats
174. Depressor effect of kappa opioid agonist on hypertension induced by isolation in the rat
175. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal
176. The effects of drugs interacting with opioid receptors in the early ventricular arrhythmias arising from myocardial ischaemia
177. The stimulatory effects of opioids and their possible role in the development of tolerance
178. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia
179. Central effects of opioid agonists and naloxone on blood pressure and heart rate in normotensive and hypertensive rats
180. Benzeneacetamide amines: Structurally novel non-μ opioids
181. 3H]U69,593 binding sites in the rat heart by receptor binding assays
182. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits
183. Haemodynamic effects of intravenous morphine in patients with acute myocardial infarction complicated by severe left ventricular failure
184. Time window for the contribution of the delta-opioid receptor to cardioprotection by ischemic preconditioning in the rat heart
185. Cardiac actions of opioids
186. Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents
187. Inhibition of L-type calcium currents in guinea pig ventricular myocytes by the kappa-opioid agonist U50488H does not involve binding to opiate receptors
188. Delta and mu receptor agonists correlate with greater depression of cardiac function than morphine sulfate in perfused rat hearts
189. Opioid receptors in rat cardiac sarcolemma: Effect of phenylephrine and isoproterenol
190. A comparison of putative kappa receptor agonists: Analgesic mechanisms and narcotic antagonist activity in mice
191. U-50,488H, a selective kappa opioid agonist: Comparison to other reputed kappa agonists
192. U-50,488H (trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]- benzeneacetamide): Prototype for a new class of opioid analgesics
193. U-50,488H: A selective and structurally novel non-mu (fs) opioid agonist
194. Mu opiate receptor: cDNA cloning and expression
195. Receptors mediating depressor responses to intrahippocampal injection of L-glutamate and dynorphin-A(1-8) in conscious, spontaneously hypertensive and normotensive Wistar-Kyoto rats
196. Dynorphin and vasopressin: Common localization in magnocellular neurons
197. Sympathetic noradrenergic fibers as the source of immunoreactive alpha-neoendorphin and dynorphin in the guinea pig heart
198. Proenkephalin- and prodynorphin-derived opioid peptides in guinea-pig heart
199. Tissue distribution of opioid receptor gene expression in the rat
200. Cardiac antiarrhythmic evolution of naloxone with or without propranolol using a modified chloroform-hypoxia screening test in the rat
201. Effects of drugs interacting with opioid receptors during normal perfusion or ischemia and reperfusion in the isolated rat heart - An attempt to identify cardiac opioid receptor subtype(s) involved in arrhythmogenesis
202. Kappa-opioid receptor antisense oligonucleotide injected into rat hippocampus causes hypertension
203. The mode of action of several opioids on cardiac muscle
204. Effects of chronic U50,488H treatment on binding and mechanical responses of the rat hearts
205. Primary structure and functional expression of a guinea pig κ opioid (dynorphin) receptor
206. Differential binding of opioid peptides and other drugs to two subtypes of opioid delta ncx binding sites in mouse brain: Further evidence for delta receptor heterogeneity
207. Nuclear factor-kappa B plays an essential role in the late phase of ischemic preconditioning in conscious rabbits
208. Differential binding domains of peptide and non-peptide ligands in the cloned rat kappa opioid receptor
209. Mechanism of diuretic action of U-62,066E, a κ opioid receptor agonist
210. Inhibition of elevated arginine vasopressin secretion in response to osmotic stimulation and acute haemorrhage by U-62,066E, a κ-opioid receptor agonist
211. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain
212. SAR evidence that antiarrhythmic activity is unrelated to opioid kappa agonist activity
213. Naloxone blocks the cardiac effects of myocardial ischemia and reperfusion in the rat isolated heart
214. Multiplicity of kappa opioid receptor binding in the rat cardiac sarcolemma
215. Developmental expression of the mu, kappa, and delta opioid receptor mRNAs in mouse